4D Molecular Therapeutics (FDMT) Share-based Compensation (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Share-based Compensation of $4.5 million for Q1 2026, down 36.26% year-over-year from $7.0 million in Q1 2025, and down 19.81% quarter-over-quarter from $5.6 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Share-based Compensation (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Share-based Compensation for 7 consecutive years, with $4.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 36.26% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $19.5 million (down 42.83% YoY), while the FY2025 annual figure was $34.2 million, down 37.25% from the prior year.
- Share-based Compensation fell to $4.5 million in Q1 2026 per FDMT's latest filing, from $5.6 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $14.5 million in Q4 2024 and bottomed at $3.9 million in Q1 2022.
- Historically, Share-based Compensation has averaged $5.7 million across 5 years, with a median of $5.0 million in 2025.
- Annual changes were most pronounced in 2022 — Share-based Compensation jumped 722.8% — and 2025, when it tumbled 61.78%.
- 4D Molecular Therapeutics' Share-based Compensation stood at $4.3 million in 2022, then soared by 36.06% to $5.9 million in 2023, then jumped by 145.71% to $14.5 million in 2024, then sank by 61.78% to $5.6 million in 2025, then declined by 19.81% to $4.5 million in 2026.
- Business Quant data shows FDMT's Share-based Compensation at $4.5 million in Q1 2026, $5.6 million in Q4 2025, and $4.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 5.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.88 Mn |
| Jun 30, 2026 | 5.88 Mn |
| Mar 31, 2026 | 4.45 Mn |
| Mar 31, 2026 | 4.45 Mn |
| Dec 31, 2025 | 5.55 Mn |
| Dec 31, 2025 | 5.55 Mn |
| Sep 30, 2025 | 4.52 Mn |
| Sep 30, 2025 | 4.52 Mn |
| Jun 30, 2025 | 4.96 Mn |
| Jun 30, 2025 | 4.96 Mn |
| Mar 31, 2025 | 6.99 Mn |
| Mar 31, 2025 | 6.99 Mn |
| Dec 31, 2024 | 14.53 Mn |
| Dec 31, 2024 | 14.53 Mn |
| Sep 30, 2024 | 6.49 Mn |
| Sep 30, 2024 | 6.49 Mn |
| Jun 30, 2024 | 6.07 Mn |
| Jun 30, 2024 | 6.07 Mn |
| Mar 31, 2024 | 5.97 Mn |
| Mar 31, 2024 | 5.97 Mn |